Avacta Group PLC (AVCT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -93.806x

Based on the latest financial reports, Avacta Group PLC (AVCT) has a cash flow conversion efficiency ratio of -93.806x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.51 Million ≈ $-1.64K USD) by net assets (GBX144.00K ≈ $17.52 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Avacta Group PLC balance sheet independence to measure how much of total assets are equity-financed.

Avacta Group PLC - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how Avacta Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Avacta Group PLC (AVCT) cash flow to debt to assess how comfortably operating cash covers total debt obligations.

Avacta Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Avacta Group PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Vinvest Capital Holdings Bhd
KLSE:0069
-0.012x
Decent Holding Inc Ordinary Shares
NASDAQ:DXST
-0.368x
Super Spinning Mills Limited
NSE:SUPERSPIN
0.038x
Future PLC
LSE:FUTR
0.068x
California Software Company Limited
NSE:CALSOFT
-0.032x
Moho Resources Ltd
AU:MOH
-0.204x
Duksung Co Ltd
KO:004835
0.003x
Revelation Biosciences Inc
NASDAQ:REVB
-0.248x

Annual Cash Flow Conversion Efficiency for Avacta Group PLC (2001–2024)

The table below shows the annual cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Avacta Group PLC worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX9.28 Million
≈ $1.13K
GBX-23.60 Million
≈ $-2.87K
-2.543x -272.78%
2023-12-31 GBX21.80 Million
≈ $2.65K
GBX-14.87 Million
≈ $-1.81K
-0.682x +23.47%
2022-12-31 GBX18.44 Million
≈ $2.24K
GBX-16.43 Million
≈ $-2.00K
-0.891x -79.15%
2021-12-31 GBX41.22 Million
≈ $5.02K
GBX-20.51 Million
≈ $-2.49K
-0.497x -189.48%
2020-12-31 GBX61.93 Million
≈ $7.53K
GBX-10.64 Million
≈ $-1.29K
-0.172x +32.71%
2018-07-31 GBX21.41 Million
≈ $2.61K
GBX-5.47 Million
≈ $-665.30
-0.255x -79.97%
2017-07-31 GBX29.89 Million
≈ $3.64K
GBX-4.24 Million
≈ $-516.01
-0.142x -20.19%
2016-07-31 GBX35.86 Million
≈ $4.36K
GBX-4.23 Million
≈ $-515.03
-0.118x +10.19%
2015-07-31 GBX19.13 Million
≈ $2.33K
GBX-2.52 Million
≈ $-306.00
-0.131x -352.36%
2014-07-31 GBX28.84 Million
≈ $3.51K
GBX-838.00K
≈ $-101.96
-0.029x +67.18%
2013-07-31 GBX15.55 Million
≈ $1.89K
GBX-1.38 Million
≈ $-167.54
-0.089x -111.16%
2012-07-31 GBX16.96 Million
≈ $2.06K
GBX-711.00K
≈ $-86.51
-0.042x +19.54%
2011-07-31 GBX11.44 Million
≈ $1.39K
GBX-596.00K
≈ $-72.52
-0.052x +70.16%
2010-07-31 GBX9.97 Million
≈ $1.21K
GBX-1.74 Million
≈ $-211.83
-0.175x +48.24%
2009-07-31 GBX8.30 Million
≈ $1.01K
GBX-2.80 Million
≈ $-340.56
-0.337x -26.84%
2008-07-31 GBX4.87 Million
≈ $592.42
GBX-1.29 Million
≈ $-157.56
-0.266x +44.06%
2007-07-31 GBX2.63 Million
≈ $319.87
GBX-1.25 Million
≈ $-152.09
-0.475x +95.21%
2006-04-30 GBX14.00K
≈ $1.70
GBX-139.00K
≈ $-16.91
-9.929x -148.21%
2005-04-30 GBX21.00K
≈ $2.56
GBX-84.00K
≈ $-10.22
-4.000x -916.22%
2004-04-30 GBX1.03 Million
≈ $125.81
GBX-407.00K
≈ $-49.52
-0.394x -315.55%
2003-04-30 GBX-230.00K
≈ $-27.98
GBX-42.00K
≈ $-5.11
0.183x -8.87%
2002-04-30 GBX-529.00K
≈ $-64.36
GBX-106.00K
≈ $-12.90
0.200x -47.29%
2001-04-30 GBX-363.00K
≈ $-44.17
GBX-138.00K
≈ $-16.79
0.380x --

About Avacta Group PLC

LSE:AVCT UK Biotechnology
Market Cap
$3.65 Million
GBX29.98 Billion GBX
Market Cap Rank
#29106 Global
#544 in UK
Share Price
GBX68.50
Change (1 day)
+3.01%
52-Week Range
GBX43.25 - GBX89.00
All Time High
GBX274.91
About

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more